Member Info for Uncanny

Indeed noise/ OilB, Roses and January are now swimming against the tide as sentiment has changed to the positive upside. They have had their fun during May but now its the long invested shareholders time to cheer!

Valju, l would say that is probably dealing by phone only for the next few sessions.

January, you are not invested so l wouldn’t book your holiday yet. Lol

Good find Marmited and l wouldn’t be surprised if VAL / ABO were to do the same: “We aim to provide companies the flexibility they need to achieve their goals. In this case, the amendment to the financing agreement gives Oncology Venture greater control over its dilution which will benefit its shareholders, whilst providing the funds it needs to develop its pipeline” said Pierre Vannineuse, CEO and founder of London based Alpha Blue Ocean Investment Group and Head of European High Growth Opportunities Securitization Fund. That would be welcomed news.

So they we have it, the proofs in the pudding and two of the same deramping colluders reply within a minute!

Valju So deramping collusion going on, shameful pack of wolves, trying to dominate stock BB’s by spreading worry, fear and panic to investors that are using their own hard earned money to make a difference to their families lives. They will meet their maker one day!

January, l disagree with your valuation. The average AIM listed junior bio at P2 is valued at between £20 to £25 million which with 753 million shares in issue is circa 3p for VAL. Thats not allowing for a completed ABO financing deal to fund ALL compound completion, 401 and 101 / FIT JV details and of course this month, 201 P1/2 escalation news and possibly a 201 licensing deal too.

Lol lsle. Expecting another bout of strong buying tomorrow to keep the momentum going.

Well that is what we are waiting for Roses.

Isle, and with the investors VAL’s SP is going to go boom! LOL

Well we have arrived now! Here is the Dec 2017 RNS which made me invest: ValiRx PLC re: VAL201 Clinical Trials Source: UK Regulatory (RNS & others) TIDMVAL RNS Number : 5685Z ValiRx PLC 18 December 2017 VALIRX PLC ("ValiRx" or the "Company") ENHANCEMENT OF THE VAL201 DOSE ESCALATION CLINICAL STUDY "Approval received from the UK Medicines and Healthcare Products Regulatory Agency ("MHRA") and the Research Ethics Committee ("REC")" London, UK., 18 December 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the Company has received approval from the MHRA and REC for the Company to expand its VAL201 trial for the Phase I/II Dose Escalation Study in Patients with Locally Advanced or Metastatic Prostate Cancer and other Advanced Solid Tumours. VAL201 has demonstrated consistently high safety and tolerability, as well as preliminary effectiveness throughout the clinical study. Following the successful completion of this stage one of clinical development, with no serious drug related adverse events noted, the MHRA and REC have accepted the Company and clinical team's request for this escalation to the study. This approval allows for a substantial increase in the dose of VAL201 being administered to patients, thereby allowing treatment to more speedily reach its full therapeutic potential and potential anti-cancer impact. Further analysis will be provided in due course following a more comprehensive evaluation of the data. This regulatory approval permits ValiRx to; -- To substantially raise the dosing level in patients in order to reach therapeutic levels and reduce disease progression; -- To assess at what stage in disease development the compound can be most effectively deployed in subsequent, larger, outcome-oriented clinical trials; and -- To determine which route and with whom to take the project to its next stage - by the Company or with a partner. VAL201 has the potential to target hormone induced oncological conditions and abnormal growths, including prostate, breast and ovarian cancers as well as endometriosis. VAL201 is currently in Phase I/II clinical trials at UCLH for prostate cancer. The compound has also shown effects against Endometriosis in pre-clinical studies. The VAL201 treatment is differentiated from current advanced prostate cancer therapies, by not including complete and general androgen hormone deprivation. The molecule is a peptide that inhibits the interaction between the androgen receptor and/or the oestrogen receptor complex with Src Kinase complex Domain 3. This very specific mode of action has been shown in pre-clinical studies to provide a potent therapeutic benefit with fewer side effects compared to the standard hormone therapy. VAL201 is potentially and uniquely able to treat prostate cancer without many of the other debilitating side effects associated with ot

https://www.britishbulls.com/m/SignalList.aspx?lang=en&MarketSymbol=LSE&seoMainContent_SignalListGrid1=page40%257csort1%257ca0

Were going rocket

It’s not working Jan. Massive spike up on Mon! Getting my money together cos its reversal

Boys its Saturday and time to relax before we see the next spike on Monday leading in to the new (hopefully) deferred 12 month exercise of loans, by which time we’ll have meat on the bones for 101 and 401, plus 201 escalation which l hope gets to the same as Pfizers and JnJ’s global leading drugs without the horrible side effects and who knows for 401? Exciting times!

Jan, don’t give the moral crusader bo!!ocks, it so transparent. Its quite simple there those invested and want VAL to do well and prosper and there are those that want the opposite. Now its not rocket science to work out which posters are on which side of the fence. Anyway, looks like VAL has got a nice financing gee gee to get its products to commercialisation and for me that is all that matters.

Roses and January Trying to influence peoples minds or convince them of your perspective before Monday is futile. Everyone sitting tight so you can post a 1000 posts over the weekend but its not going to make a jot of difference to any investors here. May as well turn off and enjoy the lively weather.

Can you confirm roses?

How much do oncology compounds sell for?

Is Roses and January the same poster?